CDX2 + CK7

CDX2 + CK7

Pack Size Cat No
3.0 mL Predilute AC012-3D
6.0 mL Predilute AC012-6D

Description

CDX2 is used in diagnostic surgical pathology as a marker for gastrointestinal differentiation, especially colorectal. Hepatocellular carcinomas show no expression of CDX2. CDX2 expression can be seen, however, in selected non-GI adenocarcinomas such as mucinous ovarian carcinomas and adenocarcinomas of the urinary bladder.

Cytokeratin 7 is a basic cytokeratin and is expressed in epithelial cells of ovary, lung and breast, but not in the colon or gastrointestinal tract. It is often used in conjunction with Cytokeratin 20 in distinguishing pulmonary ovarian and breast carcinomas (CK7 +) from colon carcinomas (CK7-).

Multiplex cocktail of CDX2 and CK7 can be used to distinguish colon cancers from breast, lung and ovarian cancers. CDX-2 will stain the nuclei brown and CK7 will stain target antigens red.

Specifications

Alternative Name
Species Rabbit + Mouse
Clone
Isotype
Dilution Range Assay dependent
Species Reactivity Human
Application IHC
Cell Localization Cytoplasm & Membrane
Positive Control

DataSheet & SDS

Download Data Sheet
Download SDS Sheet

References

1. JING LI et al, Concomitant depletion of PTEN and p27 and overexpression of cyclin D1 may predict a worse prognosis for patients with post-operative stage II and III colorectal cancer, Oncol Lett. 2014, Oct 8, p-1543–1550.

2. Edith A. Perez et al,   Impact of PTEN Protein Expression on Benefit from Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial, J Clin Oncol. 2013 Jun 10, p-2115–2122.

3. Daphne Gschwantler-Kaulich et al, PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer, PLoS One. 2017 Mar.

Request More Information

We would like to get in touch with you for any enquiry related to Pricing/Offer/Product Quotation, Order Support, and Technical Support.

 

Subject *

Name *

Email *

Phone No

Organization

Attach File, if any

Comments